How to choose the initial drug treatment for overactive bladder.
Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.
MacDiarmid
Scott A
SA
Alliance Urology Specialists, Bladder Control and Pelvic Pain Center, 509 N. Elam Avenue, Greensboro, NC 27403, USA. smacdiarmid@allianceurology.com
D003657:Decision Making; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D018579:Patient Selection; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*; D014563:Urodynamics
D018727:Muscarinic Antagonists